These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33901801)

  • 21. Targeting of tolerogenic dendritic cells towards heat-shock proteins: a novel therapeutic strategy for autoimmune diseases?
    Jansen MAA; Spiering R; Broere F; van Laar JM; Isaacs JD; van Eden W; Hilkens CMU
    Immunology; 2018 Jan; 153(1):51-59. PubMed ID: 28804903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.
    Feng PH; Lee KY; Chang YL; Chan YF; Kuo LW; Lin TY; Chung FT; Kuo CS; Yu CT; Lin SM; Wang CH; Chou CL; Huang CD; Kuo HP
    Am J Respir Crit Care Med; 2012 Nov; 186(10):1025-36. PubMed ID: 22955317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients.
    Jordan KR; Amaria RN; Ramirez O; Callihan EB; Gao D; Borakove M; Manthey E; Borges VF; McCarter MD
    Cancer Immunol Immunother; 2013 Nov; 62(11):1711-22. PubMed ID: 24072401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?
    Hilkens CM; Isaacs JD
    Clin Exp Immunol; 2013 May; 172(2):148-57. PubMed ID: 23574312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual roles of myeloid-derived suppressor cells in various diseases: a review.
    Nepal MR; Shah S; Kang KT
    Arch Pharm Res; 2024 Jul; 47(7):597-616. PubMed ID: 39008186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloid suppressor cells in cancer and autoimmunity.
    Sica A; Massarotti M
    J Autoimmun; 2017 Dec; 85():117-125. PubMed ID: 28728794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.
    Moorman CD; Sohn SJ; Phee H
    Front Immunol; 2021; 12():657768. PubMed ID: 33854514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interactions among myeloid regulatory cells in cancer.
    Umansky V; Adema GJ; Baran J; Brandau S; Van Ginderachter JA; Hu X; Jablonska J; Mojsilovic S; Papadaki HA; Pico de Coaña Y; Santegoets KCM; Santibanez JF; Serre K; Si Y; Sieminska I; Velegraki M; Fridlender ZG
    Cancer Immunol Immunother; 2019 Apr; 68(4):645-660. PubMed ID: 30003321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human trophoblast cells induced MDSCs from peripheral blood CD14(+) myelomonocytic cells via elevated levels of CCL2.
    Zhang Y; Qu D; Sun J; Zhao L; Wang Q; Shao Q; Kong B; Zhang Y; Qu X
    Cell Mol Immunol; 2016 Sep; 13(5):615-27. PubMed ID: 26027727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myeloid-derived suppressor cells prevent type 1 diabetes in murine models.
    Yin B; Ma G; Yen CY; Zhou Z; Wang GX; Divino CM; Casares S; Chen SH; Yang WC; Pan PY
    J Immunol; 2010 Nov; 185(10):5828-34. PubMed ID: 20956337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
    Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
    J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.
    Xu W; Dong J; Zheng Y; Zhou J; Yuan Y; Ta HM; Miller HE; Olson M; Rajasekaran K; Ernstoff MS; Wang D; Malarkannan S; Wang L
    Cancer Immunol Res; 2019 Sep; 7(9):1497-1510. PubMed ID: 31340983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloid-derived suppressor cells in immunity and autoimmunity.
    Yang H; Bi Y; Han F; Lu Y; Wang J; Zhang Z; Liu G
    Expert Rev Clin Immunol; 2015; 11(8):911-9. PubMed ID: 26028421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Innate immunity as the trigger of systemic autoimmune diseases.
    Saferding V; Blüml S
    J Autoimmun; 2020 Jun; 110():102382. PubMed ID: 31883831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD14
    Bernsmeier C; Triantafyllou E; Brenig R; Lebosse FJ; Singanayagam A; Patel VC; Pop OT; Khamri W; Nathwani R; Tidswell R; Weston CJ; Adams DH; Thursz MR; Wendon JA; Antoniades CG
    Gut; 2018 Jun; 67(6):1155-1167. PubMed ID: 28592438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo ablation of plasmacytoid dendritic cells inhibits autoimmunity through expansion of myeloid-derived suppressor cells.
    Ioannou M; Alissafi T; Boon L; Boumpas D; Verginis P
    J Immunol; 2013 Mar; 190(6):2631-40. PubMed ID: 23382560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA.
    Derdelinckx J; Mansilla MJ; De Laere M; Lee WP; Navarro-Barriuso J; Wens I; Nkansah I; Daans J; De Reu H; Jolanta Keliris A; Van Audekerke J; Vanreusel V; Pieters Z; Van der Linden A; Verhoye M; Molenberghs G; Hens N; Goossens H; Willekens B; Cras P; Ponsaerts P; Berneman ZN; Martínez-Cáceres EM; Cools N
    J Neuroinflammation; 2019 Aug; 16(1):167. PubMed ID: 31416452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Paradigms of Tolerogenic Dendritic Cells and Clinical Implications for Systemic Lupus Erythematosus.
    Ritprajak P; Kaewraemruaen C; Hirankarn N
    Cells; 2019 Oct; 8(10):. PubMed ID: 31640263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment.
    Gonzalez-Junca A; Driscoll KE; Pellicciotta I; Du S; Lo CH; Roy R; Parry R; Tenvooren I; Marquez DM; Spitzer MH; Barcellos-Hoff MH
    Cancer Immunol Res; 2019 Feb; 7(2):306-320. PubMed ID: 30538091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines.
    Chen HW; Chen HY; Wang LT; Wang FH; Fang LW; Lai HY; Chen HH; Lu J; Hung MS; Cheng Y; Chen MY; Liu SJ; Chong P; Lee OK; Hsu SC
    J Immunol; 2013 May; 190(10):5065-77. PubMed ID: 23589610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.